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Summary
Background: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) appears to be
involved in atherosclerotic plaque vulnerability and rupture. Circulating soluble LOX-1 (sLOX-1)
levels are dramatically elevated in patients with acute coronary syndrome (ACS), and its diag-
nostic sensitivity and speciﬁcity is superior to high-sensitivity C-reactive protein (hs-CRP). In
this study, we have compared the diagnostic value of sLOX-1 for ACS with those of troponin T
(TnT) and heart-type fatty acid binding protein (H-FABP).
Methods: One hundred and seven patients who underwent coronary angiography (CAG), includ-
ing 18 ACS and 89 non-ACS patients were enrolled. Peripheral blood samples were obtained
during the emergent or elective CAG. The non-ACS group consisted of 30 patients with nor-
mal CAG, 30 stable angina pectoris patients controlled by medical treatment, and 29 patients
with stable angina who required elective coronary revascularization (percutaneous coronary
intervention or coronary artery bypass graft).
Results: Age, gender, lipid proﬁles, or prevalence of diabetes, smoking, or hypertension were
not signiﬁcantly different between ACS and non-ACS. These factors did not signiﬁcantly affect
blood sLOX-1 levels. Circulating sLOX-1, TnT, and H-FABP levels were signiﬁcantly higher in ACS
than non-ACS. Area under the curve (AUC) values of the receiver-operating characteristic curves
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were 0.948, 0.704, and 0.691 for sLOX-1, TnT, and H-FABP, respectively. In a TnT-negative
(<0.03 ng/mL) subgroup, the AUC values for sLOX-1 and H-FABP were 0.848 and 0.476, respec-
tively.
Conclusion: Circulating sLOX-1 is a more sensitive and speciﬁc biomarker for ACS than TnT and
nal diagnostic values when measured in combination with TnT.
ardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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centrations of sLOX-1 were determined by a sandwich
chemiluminescent enzyme immunoassay (CLEIA) using twoH-FABP, and provides additio
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cute coronary syndrome (ACS) is one of the major causes
f mortality and morbidity in developed countries. Accu-
ate diagnosis of ACS, at the earliest stage, would improve
he prognosis by appropriate treatment without delay. ACS
ppears to be provoked by rupture, or erosion, of lipid-
ich atheromatous plaques followed by thrombus formation
1,2]. Several diagnostic tests, such as electrocardiogram
ECG), echocardiography [3], radioisotope scintigraphy [4],
nd measurement of circulating levels of MB isoform of
reatine kinase (CPK) [5], troponin T (TnT) [6,7], and heart-
ype fatty acid binding protein (H-FABP) [8—10] have been
tilized to detect ischemic myocardial damage in clin-
cal practice. However, TnT or H-FABP may not always
e elevated at the earliest stages of ACS, especially in
ases of non-ST-elevation ACS (NSTE-ACS), before myocar-
ial necrosis or ischemic damage becomes apparent. Certain
iomarkers for plaque instability or rupture would make it
ossible to diagnose ACS from the earliest stage, and, fur-
hermore, may predict the ACS onset.
Lectin-like oxidized low-density lipoprotein receptor-1
LOX-1) is a receptor for atherogenic oxidized low-density
ipoprotein (Ox-LDL), whose expression is not constitu-
ive but dynamically inducible by proinﬂammatory stimuli,
ngiotensin II, and Ox-LDL, which affects atherosclerotic
rogression and plaque vulnerability [11—17]. In human
therosclerotic lesions, LOX-1 is prominently expressed by
ntimal smooth muscle cells and lipid-laden macrophages
n advanced plaques [18]. Furthermore, LOX-1 plays an
mportant role in Ox-LDL-induced apoptosis of vascular
ndothelial and smooth muscle cells [19—21] and production
f matrix metalloproteinases [22], which may thus directly
e linked to the plaque vulnerability and rupture. Further-
ore, LOX-1 expression was associated with the instability
f atherosclerotic plaques in a hypercholesterolemic animal
odel [23—25].
LOX-1 expressed on the cell-surface can be prote-
lytically cleaved at its membrane-proximal extracellular
omain and released as soluble LOX-1 (sLOX-1) [26]. Cleav-
ge of LOX-1 from the cell-surface appears to be mediated
y certain metalloproteinases, including ADAM10, and to
e regulated dynamically by proinﬂammatory stimuli [27].
n previous reports, we have shown that circulating sLOX-
levels are signiﬁcantly elevated in ACS from its earlytage [28,29]. Furthermore, receiver-operating character-
stic (ROC) curves showed that diagnostic sensitivity and
peciﬁcity of sLOX-1 for ACS were much higher than those of
igh-sensitivity C-reactive protein (hs-CRP) [28]. In addition,
he diagnostic sensitivity and speciﬁcity were almost equal
d
r
b
e
sven in NSTE-ACS alone [28]. The present study, therefore,
as further compared diagnostic sensitivity and speciﬁcity
ith those of TnT and H-FABP, both of which are currently
sed as diagnostic blood biomarkers for ACS in clinical prac-
ice.
aterials and methods
atient sample
ne hundred and seven patients (18 ACS and 89 non-
CS) undergoing coronary angiography (CAG), from whom
nformed consent and blood samples were obtained and
heir TnT and H-FABP date were available, at the Cardio-
ascular Center in Osaka Red Cross Hospital were enrolled.
eripheral blood samples were obtained immediately after
mergent (ACS) or scheduled (non-ACS) CAG. ACS was
eﬁned as acute onset of prolonged chest pain or discom-
ort, which was accompanied by ST-segment elevation or
epression evolving into pathological Q waves or T wave
nversion and emergency CAG-documented total occlusion
r marked delayed ﬁlling of a coronary artery, as previously
escribed [28]. The non-ACS group (n = 89) consisted of 30
atients without any signiﬁcant luminal narrowing in CAG,
0 stable angina pectoris patients controlled by medical
reatment, and 29 patients with stable angina who required
lective coronary revascularization (percutaneous coronary
ntervention or coronary artery bypass graft) [28]. Patients
ith vasospastic angina, symptomatic peripheral vascular
iseases, or stroke were excluded from this study. Informed
onsent was obtained from the involved patients. This study
as carried out in accordance with the principles of the
eclaration of Helsinki and had been approved by the local
thics committee.
easurement of soluble LOX-1 and other
iomarkers
eripheral blood samples were obtained immediately after
mergent or scheduled CAG. Serum was obtained by
entrifugation, and samples were stored at −80 ◦C. Con-ifferent human LOX-1-speciﬁc monoclonal antibodies as
ecently described [30]. Standard curves were obtained
y the use of a recombinant protein corresponding to the
xtracellular domain of human LOX-1. This CLEIA showed
ufﬁcient correlation with our previously described sand-
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Table 1 Characteristics of patients.
Total ACS Non-ACS p-Value
Patient numbers 107 18 89
Age (years) 64.2± 11.4 62.6± 14.3 65.3± 10.3 0.359
Male (%) 66.7 66.9 65.7 0.786
Diabetes (%) 30.5 35.3 29.6 0.774
Smoking (%) 35.2 41.2 34.1 0.589
Hypertension (%) 43.0 23.1 46.9 0.144
Total cholesterol (mg/dL) 191.5± 34.8 174.6± 34.9 194.0± 3 4.3 0.0845
Triglycerides (mg/dL) 129.7± 61.3 104.4± 30.7 133.5± 64.0 0.125
43.6± 11.0 47.8± 14.3 0.335
113.5± 34.4 118.5± 32.7 0.623
density lipoprotein; LDL, low-density lipoprotein.
terol (43.6± 11.0mg/dL versus 47.8± 14.3mg/dL,
p = 0.335) nor low-density lipoprotein (LDL) cholesterol
(113.5± 34.4mg/dL versus 118.5± 32.7mg/dL, p = 0.623)
levels were signiﬁcantly different between ACS and non-ACS
groups.
Conventional cardiovascular risk factors and lipid
proﬁles versus soluble LOX-1, TnT and H-FABP
The correlation of blood biomarkers, such as sLOX-1, TnT,
and H-FABP, with conventional cardiovascular risk fac-
tors and serum lipid proﬁles was explored. As shown in
Table 2, circulating sLOX-1 levels were not signiﬁcantly
correlated with age (Spearman’s  = 0.0304, p = 0.758),
total cholesterol (Spearman’s  =−0.184, p = 0.937), triglyc-
erides (Spearman’s  =−0.133, p = 0.211), HDL cholesterol
(Spearman’s  =−0.141, p = 0.185) or LDL cholesterol (Spear-
man’s  =−0.0223, p = 0.827). In addition, sLOX-1 levels
were not signiﬁcantly different between male or female
(median: 0.121 versus 0.101 ng/mL, p = 0.370) or between
with and without conventional risk factors, such as diabetes
(median: 0.114 versus 0.104 ng/mL, p = 0.895), smoking
(median: 0.101 versus 0.122 ng/mL, p = 0.641), or hyper-
tension (median: 0.104 versus 0.098 ng/mL, p = 0.522)
(Table 3). On the other hand, TnT levels were not
signiﬁcantly correlated with age (Spearman’s  = 0.0133,
p = 0.893) although H-FABP levels were signiﬁcantly cor-
related with age (Spearman’s  = 0.201, p = 0.0398), as
previously described [31]. In addition, neither TnT nor
H-FABP levels were signiﬁcantly correlated with total
cholesterol (TnT: Spearman’s  =−0.134, p = 0.223; H-FABP:
Spearman’s  = 0.150, p = 0.174), triglycerides (TnT: Spear-
Table 2 Correlation of soluble lectin-like oxidized low-
density lipoprotein receptor-1 with age and lipid proﬁles.
Spearman  p-value
Age 0.0304 0.758
Total cholesterol −0.184 0.0937HDL cholesterol (mg/dL) 47.2± 14.0
LDL cholesterol (mg/dL) 117.8± 32.7
Values are mean± S.D. ACS, acute coronary syndrome; HDL, high-
wich enzyme-linked immunosorbent assay (ELISA) by the
use of two polyclonal antibodies [28,29], and the lower
limit of the detection for sLOX-1 was 0.008 ng/mL [30]. TnT
and H-FABP concentrations were measured by commercially
available electro-chemiluminescent immunoassay (ECLIA,
Roche Diagnostic, Basel, Switzerland) and ELISA (Marco Phar-
maceutical, Tokyo, Japan), respectively. All the assays were
carried out by personnel who had no knowledge of the clin-
ical diagnosis of the patients.
Statistical analysis
The distribution of sLOX-1, TnT, and H-FABP was skewed;
therefore, Wilcoxon/Kruskal—Wallis test was utilized.
ANOVA was applied for other clinical parameters. Associa-
tion of sLOX-1 with other values, including TnT and H-FABP,
was evaluated by Spearman’s rank-correlation coefﬁcient.
ROC analysis was carried out on the levels of sLOX-1, TnT,
and H-FABP for ACS with non-ACS as a negative control
group. This analysis plots the true positive fraction (sen-
sitivity) against the false positive fraction (1-speciﬁcity) by
changing the cut-off value for the test. Areas under the ROC
curves indicate the relative accuracy of diagnostic tests.
p-Values less than 0.05 were considered statistically signiﬁ-
cant.
Results
Clinical characteristics of study subjects
Table 1 summarizes the clinical characteristics of the
subjects enrolled in this study. Age, gender, conventional
cardiovascular risk factors, such as diabetes, smoking
hypertension, and lipid proﬁles, were compared between
ACS and non-ACS groups. Age (62.6± 14.3 years versus
65.3± 10.3 years, p = 0.359), gender (male %: 66.9% ver-
sus 65.7%, p = 0.786), or prevalence of diabetes (35.3%
versus 29.6%, p = 0.774), smoking (41.2% versus 34.1%,
p = 0.589) or hypertension (23.1% versus 46.9%, p = 0.144)
were not signiﬁcantly different between the ACS and non-
ACS groups. In addition, neither serum total cholesterol
(174.6± 34.9mg/dL versus 194.0± 34.3mg/dL, p = 0.0845),
triglyceride (104.4± 30.7mg/dL versus 133.5± 64.0mg/dL,
p = 0.125), high-density lipoprotein (HDL) choles-
Triglycerides −0.133 0.211
HDL cholesterol −0.141 0.185
LDL cholesterol −0.0223 0.827
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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Table 3 Comparison of soluble lectin-like oxidized low-density lipoprotein receptor-1 levels between male and female or with
and without conventional risk factors.
Median (25th—75th percentiles) p-Value
Yes No
Male 0.121 (0.073—0.216) 0.101 (0.050—0.262) 0.370
Diabetes 0.114 (0.054—0.280) 0.104 (0.072—0.204) 0.895
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sSmoking 0.101 (0.073—0.187)
Hypertension 0.104 (0.051—0.165)
an’s  =−0.148, p = 0.163; H-FABP: Spearman’s  = 0.0195,
= 0.854), HDL cholesterol (TnT: Spearman’s  =−0.0907,
= 0.395; H-FABP: Spearman’s  = 0.0579, p = 0.588) or
DL cholesterol (TnT: Spearman’s  =−0.0347, p = 0.733;
-FABP: Spearman’s  = 0.0823, p = 0.418). Furthermore,
either TnT nor H-FABP levels were signiﬁcantly differ-
nt between males and females (TnT median: 0.01 ng/mL
ersus 0.01 ng/mL, p = 0.982; H-FABP median: 2.95 ng/mL
ersus 4.1 ng/mL, p = 0.116) or between with and with-
ut conventional risk factors, such as diabetes (TnT
edian: 0.01 ng/mL versus 0.01 ng/mL, p = 0.1584; H-FABP
edian: 3.5 ng/mL versus 3.3 ng/mL, p = 0.821), smoking
TnT median: 0.01 ng/mL versus 0.01 ng/mL, p = 0.873), and
ypertension (TnT median: 0.01 ng/mL versus 0.01 ng/mL,
= 0.0975; H-FABP median: 3.6 ng/mL versus 2.9 ng/mL,
= 0.441), except that H-FABP levels were signiﬁcantly lower
n smokers than non-smokers (median: 2.9 ng/mL versus
.8 ng/mL, p = 0.0195) in this study population.
oluble LOX-1, TnT, and H-FABP levels in ACS
n ACS cases, time intervals from the symptom onset to the
lood sampling were 4.8± 4.3 h in this study. As shown in
ig. 1, peripheral blood sLOX-1, TnT, and H-FABP levels were
emarkably higher in ACS than non-ACS (sLOX-1median, 25th
nd 75th percentiles: 1.13, 0.168, and 3.46 versus 0.096,
.0645, and 0.162 ng/mL, p < 0.0001; TnT median, 25th and
5th percentiles: 0.04, 0.01, and 0.36 versus 0.01, 0.01, and
.01 ng/mL, p = 0.0003; H-FABP median, 25th and 75th per-
entiles: 7.8, 2.9, and 100.5 versus 3.3, 2.5, and 4.9 ng/mL,
= 0.012). These differences were statistically signiﬁcant as
reviously reported [6—10,28—30]. To compare diagnostic
ensitivity and speciﬁcity for ACS, ROC curves were com-
ared among sLOX-1, TnT, and H-FABP (Fig. 2). Area under
he ROC curve (AUC) values were 0.948, 0.704, and 0.691 for
LOX-1, TnT, and H-FABP, respectively, indicating that sLOX-1
howed the highest sensitivity and speciﬁcity for ACS among
hese three biomarkers. Furthermore, ROC curves for the
iagnosis of STE-ACS alone were compared, among sLOX-
, TnT, and H-FABP, by exclusion of NSTE-ACS. Among 18
CS patients, 13 subjects were STE-ACS and 5 cases were
STE-ACS. ROC curves for STE-ACS (Fig. 3) were not so much
ifferent from those for whole ACS (Fig. 2). The AUC values
ere 0.920, 0.731, and 0.633 for sLOX-1, TnT, and H-FABP,
espectively.
In the ACS group, H-FABP values were signiﬁcantly cor-
elated with TnT values (Spearman’s  = 0.658, p = 0.003).
n contrast, sLOX-1 values were not signiﬁcantly correlated
ith TnT (Spearman’s  = 0.176, p = 0.499) or H-FABP (Spear-
a
s
ﬁ
w
i0.122 (0.067—0.266) 0.641
0.098 (0.068—0.314) 0.522
an’s  = 0.343, p = 0.178) values, indicating that sLOX-1 is
ndependent of TnT and H-FABP. To further evaluate the
iagnostic values of sLOX-1, ROC curves of sLOX-1 and H-
ABP were compared in a subpopulation whose TnT levels
ere below 0.03 ng/mL (an optimal cut-off value for ACS
iagnosis). This cut-off value showed 50% sensitivity and
3% speciﬁcity for ACS diagnosis in this study population, as
hown in Fig. 2B. In this TnT-negative subgroup (83 subjects
n total), 9 cases were ACS and 74 subjects were non-ACS.
s shown in Fig. 4, diagnostic sensitivity and speciﬁcity were
uch superior in sLOX-1; the AUC values for sLOX-1 and H-
ABP, in this TnT-negative subgroup, were 0.848 and 0.476,
espectively. Thus, sLOX-1 shows signiﬁcant diagnostic val-
es for ACS in addition to TnT; however, H-FABP may not
ppear to show any additional diagnostic values when mea-
ured in combination with TnT at the same time.
iscussion
upture or erosion of atheromatous plaques followed by
hrombus formation is considered as a crucial step in the
athogenesis of ACS. Atherosclerotic plaques with abundant
ipid-laden macrophages and activated smooth muscle cells
ith proinﬂammatory stimuli in the intima appear to be
rone to rupture [1,2]. In such vulnerable plaques, LOX-
is prominently expressed by smooth muscle cells and
acrophages [18] and contributes to apoptosis of endothe-
ial and smooth muscle cells [19—21] and production of
atrix metalloproteinases [22]. Under these conditions,
nhanced protease activities may cleave sLOX-1 from the
urface of these vascular cells, in which LOX-1 is abun-
antly expressed. Our recent studies have indicated that
DAM family proteases may be involved in LOX-1 cleavage
nd that proinﬂammatory stimuli can enhance this cleav-
ge process [27]. Therefore, the rationale for this test to
etect ACS at the earliest stage is that plaque instability
r rupture would precede the ischemic myocardial damage
hat releases TnT and H-FABP. Additionally, elevated levels
f sLOX-1 may also reﬂect platelet activation and thrombus
ormation followed by plaque erosion or rupture [32,33]. As
biomarker for platelet activation and thrombus formation,
tility of D-dimer has also been suggested [34].
In the present study, we compared diagnostic values of
LOX-1 with those of current biomarkers for ACS, such as TnT
nd H-FABP in the same blood samples, and revealed that
LOX-1 shows the highest diagnostic sensitivity and speci-
city. In addition, sLOX-1 was able to detect ACS in subjects
hose TnT levels were not signiﬁcantly elevated, indicat-
ng that diagnostic accuracy would be signiﬁcantly improved
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Figure 1 Comparison of soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1), troponin T (TnT), and heart-type
fatty acid-binding protein (H-FABP) levels between acute coronary syndrome (ACS) and non-ACS. Peripheral blood sLOX-1, TnT,
and H-FABP levels were compared between 18 ACS and 89 non-ACS subjects at the acute stage. Levels of sLOX-1 (p < 0.0001), TnT
(p = 0.0003), and H-FABP (p = 0.012) were signiﬁcantly higher in ACS than non-ACS.
Figure 2 Receiver-operating-characteristics (ROC) curves of soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-
1) (A), troponin T (TnT) (B), and heart-type fatty acid-binding protein (H-FABP) (C) for the diagnosis of acute coronary syndrome
tted
(C) f
ly.(ACS). The true positive fraction (sensitivity as Y axis) was plo
changing the cut-off values of sLOX-1 (A), TnT (B), and H-FABP
0.948, 0.704, and 0.691 for sLOX-1, TnT, and H-FABP, respectivewhen TnT and sLOX-1 are measured in combination. How-
ever, the limitation of this study appears to be the lack
of time-window analyses for the each biomarker during the
acute stage of ACS, because of the sample size and the sin-
g
f
i
r
Figure 3 Receiver-operating-characteristics (ROC) curves of solubl
1) (A), troponin T (TnT) (B) and heart-type fatty acid-binding protei
syndrome (STE-ACS). The true positive fraction (sensitivity as Y axis)
X axis) by changing the cut-off values of sLOX-1 (A), TnT (B), and H-F
Area under the ROC curve values were 0.920, 0.731, and 0.633 for sagainst the false positive fraction (1-speciﬁcity as X axis) by
or the diagnosis of ACS. Area under the ROC curve values werele blood sampling. It, therefore, would be necessary, in the
uture, to evaluate the diagnostic values in larger samples
ncluding those with acute chest symptoms in emergency
ooms, comparing the results among different time-windows
e lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-
n (H-FABP) (C) for the diagnosis of ST-elevation acute coronary
was plotted against the false positive fraction (1-speciﬁcity as
ABP (C) for the diagnosis of STE-ACS by excluding non-STE-ACS.
LOX-1, TnT, and H-FABP, respectively.
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Figure 4 Comparison of receiver-operating-characteristics (ROC) curves for the diagnosis of acute coronary syndrome (ACS)
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[etween soluble lectin-like oxidized low-density lipoprotein rec
n the troponin T (TnT)-negative subpopulation. In the TnT-ne
-FABP (B) for ACS are indicated. Area under the ROC curve val
rom the symptom onset. In addition, diagnostic sensitivity
nd speciﬁcity of sLOX-1 might be inferior to TnT at more
han 12 h after the onset of ACS, as we have previously indi-
ated the time-dependent changes in sLOX-1 and TnT levels
fter the onset of ACS [28]. Recently, high-sensitivity tro-
onins T and I have been shown to detect acute myocardial
nfarction (AMI) at the early stages [35,36]. In these large-
cale international multicenter studies, the ROC curve of
he conventional TnT to diagnose AMI appeared similar to
urs, thus indicating the appropriateness of our patient sam-
les although the size was small. Therefore, it should be
ested, in the future, whether sLOX-1 has incremental val-
es to diagnose ACS or AMI at the early stages in addition to
hese sensitive assays for troponins.
At present, furthermore, we do not know exactly when
irculating sLOX-1 levels begin to be elevated before the
nset of ACS. In our previous study, however, sLOX-1 levels
t the initial time of visit showed almost the peak values
or each patient [28]. Therefore, peripheral blood sLOX-1
evels may begin to rise before the onset of ACS in advance.
urther large-scale prospective studies, in the future, would
lso elucidate the predictive values of circulating sLOX-1 for
he onset of ACS or AMI.
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